Vascular Prothesis Infection is a rare but an extremely serious complication. Diagnosis is often difficult (germs are found only in 50% of cases). Conventional imagery is often non-specific and difficult to interpret especially in early postoperative phase. Leukocytes isolated from the patient's blood are labeled with a radiopharmaceutical technetium 99mTc-HMPAO. The aim of this study is to assess the overall diagnostic performance of scintigraphy (hybrid SPEC-CT) with labeled leucocytes in diagnosis of subdiaphragmatic vascular prothesis infection.
Full Title of Study: “Tomoscintigraphie Hybride Aux Leucocytes Marqués Dans le Diagnostic Des Infections de Prothèses Vasculaires.”
- Study Type: Interventional
- Study Design
- Allocation: N/A
- Intervention Model: Single Group Assignment
- Primary Purpose: Diagnostic
- Masking: Double (Participant, Investigator)
- Study Primary Completion Date: January 2020
- Biological: 99mTc-Exametazime (HMPAO)-labeled leukocytes
- Hybrid tomoscintigraphy with labeled leucocytes for patients with suspected vascular prosthesis infection
Arms, Groups and Cohorts
- Experimental: 99mTc-Exametazime (HMPAO)-labeled leucocytes
Clinical Trial Outcome Measures
- Percentage of patients correctly classified by interpreting scintigraphy for the diagnosis of vascular prosthesis infection. The percentage of patients correctly classified is assessed comparing with the diagnostic established by the expert committee.
- Time Frame: One year after inclusion when vascular prosthesis infection is suspected and hybrid SPEC-CT with labeled leukocytes has been performed.
- A visual analysis of scintigraphy for diagnosing vascular prosthesis infection. Scintigraphy is considered positive if at least one abnormal localization is seen at vascular prosthesis and if intensity is increasing over time on 20-24h delayed images.
Participating in This Clinical Trial
- patient of more than 18 years old – Patient with a subdiaphragmatic vascular prosthesis – Vascular prosthesis infection suspected with clinical (flow from the scare and/or local pain and/or erythema and/or persistent fever and/or bacteraemia) and/or biological (inflammatory syndrome : elevated C-reactive protein and/or erythrocyte sedimentation rate (ESR) and/or white blood cells increased) infection signs – Patient willing to participate with a signed informed consent – Patient covered by a healthcare insurance Exclusion Criteria:
- Pregnant women or of childbearing age without effective contraception – Prosthesis limited to a bare stent. – Patient who has been committed to an institution by legal or regulatory order – Contraindications for labeled leukocytes scintigraphy realization : – Restlessness, inability to keep still lie at least 1 hour – Claustrophobia – Poor compliance predictable or impaired general condition making it impossible to carry out the examination – Refusal to participate in the study
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- University Hospital, Angers
- Provider of Information About this Clinical Study
- Overall Official(s)
- HERVE RAKOTONIRINA, Dr, Principal Investigator, University hospital, Angers, FRANCE
- Overall Contact(s)
- HERVE RAKOTONIRINA, Dr, +33(0)241353412, HeRakotonirina@chu-angers.fr
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.